FDA approves Lupin’s generic Temovate ointment

The Food and Drug Administration has approved Lupin’s generic Temovate ointment (Clobetasol propionate ointment, 0.05%). The product is indicated to relieve inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, the company said.

Lupin’s generic Temovate ointment had a U.S. market size of roughly $120 million for the 12 months ended in January, according to IQVIA data.